| JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 卷:76 |
| Raising the Evidentiary Bar for Guideline Recommendations for TAVR JACC Review Topic of the Week | |
| Review | |
| Kaul, Sanjay1,2  | |
| [1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Cardiol, Los Angeles, CA 90048 USA | |
| [2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA | |
| 关键词: clinical trials; guidelines; evidence; TAVR; SAVR; | |
| DOI : 10.1016/j.jacc.2020.05.085 | |
| 来源: Elsevier | |
PDF
|
|
【 摘 要 】
On August 16, 2019, the U.S. Food and Drug Administration approved expanding the indication for transcatheter aortic valve replacement (TAVR) to low-risk patients with symptomatic severe aortic stenosis. The decision was based on the results of 2 pivotal trials that confirmed superiority (PARTNER [Placement of Aortic Transcatheter Valves] 3) or noninferiority (Evolut Low Risk [LR]) of TAVR as compared with SAVR at 1- and 2-year follow-up, respectively. As compared with intermediate-risk cohorts, the sample size in these trials was smaller and the total number of primary endpoint events was nearly 3 times as low (193 vs. 615). The total number of deaths from any cause or disabling stroke at 1 year in the low-risk cohorts was 62, which is substantially lower than the numbers in intermediate-, high-, and inoperable-risk cohorts. In Evolut LR, only 137 of 1,403 patients (9.8%) completed the 2-year follow-up, with 91.2% requiring modelbased imputation. Thus, the quantum of evidence is insufficient for endorsing TAVR as the preferred intervention for these patients. (C) 2020 by the American College of Cardiology Foundation.
【 授权许可】
Free
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| 10_1016_j_jacc_2020_05_085.pdf | 386KB |
PDF